David Younger explains that training generalizable protein design models requires hundreds of thousands of structural affinity landscapes. Even using high-throughput tools that measure a million affinities at once, funding that volume alone is nearly impossible for one firm, whereas a five-member consortium yields 28 million data points per year.
David Younger argues that federated learning relies on messy historical records and keeps participants isolated. In contrast, pooled data consortiums incentivize members to actively share experimental breakthroughs, because helping peer members design better assays directly increases the quality and volume of data distributed back to everyone.
David Younger divides the data bottleneck into generalizable model training and proprietary candidate validation. Broad target and binder diversity can be generated collaboratively in pre-competitive pools, while validating clinical assets against specific proprietary drug targets remains entirely private and isolated outside the consortium.
David Younger notes that drug companies resist sharing proprietary historical data from past pipeline projects. Instead of asking members to dig into private vaults, A Alpha Bio's consortium focuses purely on forward-looking, pre-competitive experiments where participants design shared datasets with clear visibility before testing begins.
